abstract |
The present invention finds that increased alpha 2a adrenergic receptor (ADRA2a) levels are associated with chronic liver disease, and decreasing ADRA2a levels in vivo can reduce some symptoms and consequences of chronic liver disease Derived from. Accordingly, the present invention provides an ADRA2a antagonist for use in a method of treating an individual suffering from liver disease. [Selection] Figure 1A |